Aliases & Classifications for Ocular Hypertension

MalaCards integrated aliases for Ocular Hypertension:

Name: Ocular Hypertension 12 55 44 15 73
Hypertension, Ocular 40

Classifications:



External Ids:

Disease Ontology 12 DOID:9282
ICD10 33 H40.05
ICD9CM 35 365.04
MeSH 44 D009798
NCIt 50 C3285
UMLS 73 C0028840

Summaries for Ocular Hypertension

Disease Ontology : 12 An eye disease that is characterized by elevated intraocular pressure in the absence of optic nerve damage or visual field loss.

MalaCards based summary : Ocular Hypertension, also known as hypertension, ocular, is related to glaucoma, primary open angle and open-angle glaucoma, and has symptoms including eye manifestations An important gene associated with Ocular Hypertension is MYOC (Myocilin), and among its related pathways/superpathways are Angiopoietin Like Protein 8 Regulatory Pathway and Prolactin Signaling Pathway. The drugs Dorzolamide and Acetazolamide have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and retina, and related phenotypes are homeostasis/metabolism and behavior/neurological

Wikipedia : 76 Ocular hypertension is the presence of elevated fluid pressure inside the eye (intraocular pressure),... more...

Related Diseases for Ocular Hypertension

Diseases related to Ocular Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Related Disease Score Top Affiliating Genes
1 glaucoma, primary open angle 30.0 MYOC OPTN TMCO1
2 open-angle glaucoma 30.0 MYOC OPTN PTGFR TMCO1
3 optic nerve disease 28.7 MYOC OPN4 OPTN
4 glaucoma 3, primary congenital, a 10.8
5 glaucoma 3, primary infantile, b 10.8
6 retinitis 10.4
7 cataract 10.0
8 uveitis 10.0
9 endotheliitis 10.0
10 ocular hypotension 10.0
11 apparent mineralocorticoid excess 9.9 HSD11B1 HSD11B2 NR3C1
12 exfoliation syndrome 9.9
13 glaucoma, normal tension 9.8
14 low tension glaucoma 9.8
15 neuropathy 9.8
16 glaucoma 1, open angle, a 9.8 MYOC OPTN
17 aging 9.8
18 retinal vein occlusion 9.8
19 neuroretinitis 9.8
20 macular retinal edema 9.8
21 excessive tearing 9.7 MYOC OPTN
22 macular dystrophy, dominant cystoid 9.7
23 arthritis 9.7
24 retinal ischemia 9.7
25 thrombosis 9.7
26 choroiditis 9.7
27 scleritis 9.7
28 ischemia 9.7
29 cavernous sinus thrombosis 9.7
30 thyroiditis 9.7
31 retinal degeneration 9.7
32 glycogen storage disease vi 9.6 FOS G6PC
33 intraocular pressure quantitative trait locus 9.6 MYOC OPTN
34 retinal detachment 9.5
35 glaucoma-related pigment dispersion syndrome 9.5
36 anxiety 9.5
37 graft-versus-host disease 9.5
38 diabetes mellitus 9.5
39 ischemic optic neuropathy 9.5
40 keratoconus 9.5
41 fuchs' endothelial dystrophy 9.5
42 myopia 9.5
43 nephrotic syndrome 9.5
44 primary angle-closure glaucoma 9.5
45 melanoma 9.5
46 corneal dystrophy 9.5
47 adrenal gland hyperfunction 9.5
48 retinal disease 9.5
49 herpes zoster 9.5
50 keratoconjunctivitis 9.5

Comorbidity relations with Ocular Hypertension via Phenotypic Disease Network (PDN):


Glaucoma, Primary Open Angle

Graphical network of the top 20 diseases related to Ocular Hypertension:



Diseases related to Ocular Hypertension

Symptoms & Phenotypes for Ocular Hypertension

UMLS symptoms related to Ocular Hypertension:


eye manifestations

MGI Mouse Phenotypes related to Ocular Hypertension:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.25 SRSF3 TMCO1 AKT1 CA2 EPO FKBP5
2 behavior/neurological MP:0005386 10.16 AKT1 FKBP5 FOS G6PC HSD11B1 HSD11B2
3 immune system MP:0005387 10.07 AKT1 CA2 EPO FOS HSD11B1 JUN
4 endocrine/exocrine gland MP:0005379 10.03 AKT1 CA2 FOS HSD11B1 JUN NR3C1
5 mortality/aging MP:0010768 10.03 AKT1 CA2 EPO FKBP5 FOS G6PC
6 liver/biliary system MP:0005370 9.87 SRSF3 AKT1 EPO G6PC HSD11B1 JUN
7 nervous system MP:0003631 9.85 OPN4 RLBP1 TMCO1 AKT1 CA2 FOS
8 normal MP:0002873 9.7 AKT1 EPO FKBP5 FOS G6PC HSD11B2
9 skeleton MP:0005390 9.28 AKT1 CA2 EPO FOS G6PC JUN

Drugs & Therapeutics for Ocular Hypertension

Drugs for Ocular Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 273)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dorzolamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120279-96-1 3154 5284549
2
Acetazolamide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 59-66-5 1986
3
Apraclonidine Approved Phase 4,Phase 3,Not Applicable 66711-21-5 2216
4
Ketorolac Approved Phase 4,Not Applicable 74103-06-3, 66635-83-4 3826
5
Ephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 299-42-3 9294
6
Topiramate Approved Phase 4 97240-79-4 5284627
7
Timolol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 26839-75-8 33624 5478
8
Pseudoephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 90-82-4 7028
9
Pilocarpine Approved, Investigational Phase 4,Phase 3,Not Applicable 54-71-7, 92-13-7 5910
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-02-2 5743
11
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
12
Prednisolone Approved, Vet_approved Phase 4,Not Applicable 50-24-8 5755
13
Latanoprost Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 130209-82-4 5282380 5311221
14
Brinzolamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 138890-62-7 68844
15
Bimatoprost Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 155206-00-1 5311027
16
Methylprednisolone Approved, Vet_approved Phase 4,Not Applicable 83-43-2 6741
17
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 216974-75-3
18
Travoprost Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 157283-68-6 5282226
19
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 347396-82-1 459903
20
Clonidine Approved Phase 4 4205-90-7 2803
21
Loteprednol Approved Phase 4 82034-46-6, 129260-79-3 444025 9865442
22
Diclofenac Approved, Vet_approved Phase 4,Not Applicable 15307-86-5 3033
23
Carteolol Approved Phase 4,Phase 3,Phase 1 51781-06-7 2583
24
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
25
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
26
Nitrous oxide Approved, Vet_approved Phase 4,Early Phase 1 10024-97-2 948
27
Dipivefrin Approved Phase 4,Phase 3,Not Applicable 52365-63-6 3105
28
Fluticasone Approved, Experimental, Investigational Phase 4 90566-53-3 62924
29
Sorbitol Approved Phase 4 50-70-4 5780
30
Atropine Approved, Vet_approved Phase 4,Not Applicable 5908-99-6, 51-55-8 174174
31
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
32
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Not Applicable 11103-57-4, 68-26-8 445354
33
Choline Approved, Nutraceutical Phase 4 62-49-7 305
34 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable
35
Maleic acid Experimental Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 110-16-7 444266
36 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Not Applicable
37 Prednisolone acetate Phase 4,Not Applicable
38 Brimonidine Tartrate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 70359-46-5
39 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Not Applicable 1177-87-3
40 Analgesics Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
41 Alkylating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
42 diuretics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 glucocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
44 Respiratory System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
45 Central Nervous System Depressants Phase 4,Phase 3,Not Applicable,Early Phase 1
46 Methylprednisolone acetate Phase 4,Not Applicable
47 Methylprednisolone Hemisuccinate Phase 4,Not Applicable
48 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1184)
# Name Status NCT ID Phase Drugs
1 Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Unknown status NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
2 IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids Unknown status NCT00744666 Phase 4 Prednisolone 1% topical eye drops
3 Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose Unknown status NCT02017327 Phase 4 Monoprost;Lumigan 0.01%;Lumigan 0.03% Unit Dose
4 Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy Unknown status NCT00442312 Phase 4 Combigan Ophthalmic Solutiom
5 Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of SLT vs. PLT in Patients With POAG Unknown status NCT02231515 Phase 4
6 Efficiency of XAL-EASE Device in Glaucoma and/or Ocular Hypertension (OHT) Patients, Treated With Xalatan or Xalacom Unknown status NCT01125306 Phase 4
7 Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Unknown status NCT02471105 Phase 4 Preserved Bimatoprost 0.01%;Tafluprost Unit Dose Preservative Free 15microgram/ml
8 The Impact of Topical Prostaglandins on the Biomechanical Properties of the Cornea in Patients With Open Angle Glaucoma Unknown status NCT02388360 Phase 4 topical prostaglandin analogs
9 Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients Unknown status NCT02053298 Phase 4 Timolol & Dorzolamide
10 Evaluation of the XEN Implant in Moderate POAG Subjects Unknown status NCT02006693 Phase 4
11 Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves Unknown status NCT01883856 Phase 4
12 The Laser in Pseudoexfoliation (LIP) Study Unknown status NCT01704989 Phase 4 Prostagladin
13 The Effect of "Eye Drop Guide" on the Success Rate of Eye Drops Self-instillation in Glaucoma Patients Unknown status NCT01704248 Phase 4
14 Efficacy and Safety of Three Different Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma Unknown status NCT01580254 Phase 4 IOPIZE© Latanoprost eyedrops;GALAXIA© Latanoprost eyedrops;Latanoprost RATIOPHARM© latanoprost eyedrops
15 Evaluation of Safety and Efficacy of Glaucoma Shunt (Aurolab Artificial Drainage Implant) in Refractory Glaucoma Unknown status NCT01401088 Phase 4
16 Use of Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery Unknown status NCT01229202 Phase 4 Bevacizumab
17 Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure Unknown status NCT00796198 Phase 4 Xalatan+Cosopt;Xalatan
18 ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function Unknown status NCT00485238 Phase 4 Intravenous acetazolamide
19 Subconjunctival Bevacizumab to Prevent Bleb Failure After Glaucoma Filtration Surgery Unknown status NCT00468429 Phase 4 Subconjunctival Bevacizumab
20 Ologen (OculusGen)-Glaucoma MMC Control Trial in India Unknown status NCT00449098 Phase 4 Trabeculectomy with MMC
21 The Effect of Education on Patient Compliance Unknown status NCT00376974 Phase 4
22 A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2 Unknown status NCT00326079 Phase 4
23 Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma Unknown status NCT01446497 Phase 4 Brimonidine/Timolol mixed combination;Timolol
24 Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled Trial Unknown status NCT00273221 Phase 4
25 PASCAL Trabeculoplasty Unknown status NCT00804323 Phase 4
26 Relationship Between Topiramate Use and Ocular Angle Status Unknown status NCT00153699 Phase 4 Topiramate
27 Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma Unknown status NCT01494974 Phase 4
28 An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More Completed NCT01979913 Phase 4 Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
29 Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension Completed NCT00300079 Phase 4 brinzolamide 1.0%
30 24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension Completed NCT01655758 Phase 4 0.5% timolol;timolol-dorzolamide fixed combination;Latanoprost;Travoprost;Bimatoprost
31 Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked Study Completed NCT01975714 Phase 4 Preservative-free latanoprost;Preservative-free bimatoprost
32 Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension Completed NCT00061503 Phase 4 Travoprost
33 Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension Completed NCT02571712 Phase 4 bimatoprost 0.03% plus timolol 0.5%
34 Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Completed NCT01298700 Phase 4 bimatoprost 0.01% ophthalmic solution;bimatoprost 0.03% ophthalmic solution
35 Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) Completed NCT01464424 Phase 4 Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
36 Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects Completed NCT00735449 Phase 4 Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%;timolol maleate 0.5%;latanoprost 0.005%
37 A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension Completed NCT00471380 Phase 4 travoprost 0.004% and brinzolamide 1%;fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle
38 Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED) Completed NCT00545064 Phase 4 dorzolamide hydrochloride (+) timolol maleate
39 A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma Completed NCT00647101 Phase 4 Latanoprost
40 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients Completed NCT00330577 Phase 4 timolol maleate 0.5%;latanoprost/timolol fixed combination;placebo (artificial tears)
41 Laser-1st vs Drops-1st for Glaucoma and Ocular Hypertension Completed NCT03395535 Phase 4 Primary Medical Treatment Pathway
42 Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP) Completed NCT01162603 Phase 4 TAFLUPROST 0.0015% EYEDROPS;LATANOPROST 0.005% EYEDROPS
43 Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00759239 Phase 4 Travoprost 0.004% / Timolol maleate 0.5%;Travoprost 0.004% / Timolol maleate 0.5%
44 A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Completed NCT00527592 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
45 Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00804648 Phase 4 Timolol Maleate in Sorbate;Timolol hemihydrate;Timolol maleate gel forming solution
46 Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution Completed NCT02325518 Phase 4 Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension;Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution;Subject's habitual PGA monotherapy
47 Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost Completed NCT01443988 Phase 4 Travoprost
48 Intraocular Pressure Reduction With the Bimatoprost/Timolol Fixed Combination Completed NCT00941096 Phase 4 Bimatoprost and Bimatoprost/Timolol fixed combination.
49 Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG) Completed NCT00698945 Phase 4 Istalol and Optive;Alphagan
50 Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed NCT01978600 Phase 4 Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension;Timolol Maleate 0.5%

Search NIH Clinical Center for Ocular Hypertension

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: ocular hypertension

Genetic Tests for Ocular Hypertension

Anatomical Context for Ocular Hypertension

MalaCards organs/tissues related to Ocular Hypertension:

41
Eye, Testes, Retina, Endothelial, Brain, Thyroid, Bone

Publications for Ocular Hypertension

Articles related to Ocular Hypertension:

(show top 50) (show all 711)
# Title Authors Year
1
Intravenous Hypertonic Saline to Lower Intraocular Pressure in Ocular Hypertension and Primary Open-angle and Exfoliation Glaucoma. ( 29750719 )
2018
2
Resveratrol ameliorates disorders of mitochondrial biogenesis and dynamics in a rat chronic ocular hypertension model. ( 29894715 )
2018
3
Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension. ( 29846910 )
2018
4
Knockout of tissue transglutaminase ameliorates TGFI^2-induced ocular hypertension: A novel therapeutic target for glaucoma? ( 29535003 )
2018
5
What We Have Learned From the Ocular Hypertension Treatment Study. ( 29861092 )
2018
6
P2X7 receptor antagonist protects retinal ganglion cells by inhibiting microglial activation in a rat chronic ocular hypertension model. ( 29207073 )
2018
7
Expression and activation of mitogen activated protein kinases in the optic nerve head in a rat model of ocular hypertension. ( 29408550 )
2018
8
Ocular Hypertension/Glaucoma in Minipigs: Episcleral Veins Cauterization and Microbead Occlusion Methods. ( 29190016 )
2018
9
Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension. ( 29873009 )
2018
10
Steroid-induced ocular hypertension in the pediatric age group. ( 29554813 )
2018
11
The effect of celastrol on the ocular hypertension-induced degeneration of retinal ganglion cells. ( 29398521 )
2018
12
Noninvasive evaluation of cerebrospinal fluid pressure in ocular hypertension: a preliminary study. ( 29575652 )
2018
13
Clinical outcomes of patterned laser trabeculoplasty as adjuvant therapy in open angle glaucoma and ocular hypertension. ( 29675383 )
2018
14
Transforming growth factor I^2 (TGFI^2) signaling plays a key role in glucocorticoid-induced ocular hypertension. ( 29743238 )
2018
15
Methods to Induce Chronic Ocular Hypertension: Reliable Rodent Models as a Platform for Cell Transplantation and Other Therapies. ( 29637819 )
2018
16
Prevalence of Ocular Hypertension and Glaucoma as Well as Associated Factors in Graves' Orbitopathy. ( 29557835 )
2018
17
Noninvasive Detection of Mitochondrial Dysfunction in Ocular Hypertension and Primary Open-angle Glaucoma. ( 29750714 )
2018
18
Steroid-induced protracted severe ocular hypertension in a 14-year-old girl. ( 29950368 )
2018
19
Calcium channels are involved in EphB/ephrinB reverse signalinga89induced apoptosis in a rat chronic ocular hypertension model. ( 29207174 )
2018
20
The Microbead Occlusion Model of Ocular Hypertension in Mice. ( 29190015 )
2018
21
Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma. ( 29669171 )
2018
22
What We Have Learned From the Ocular Hypertension Treatment Study. ( 29759296 )
2018
23
Glucocorticoid receptor GRI^ regulates glucocorticoid-induced ocular hypertension in mice. ( 29339763 )
2018
24
Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension. ( 29761382 )
2018
25
Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings. ( 29194198 )
2018
26
Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride. ( 29802759 )
2018
27
A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma. ( 29802818 )
2018
28
The effects of repeated Ozurdex injections on ocular hypertension. ( 29662300 )
2018
29
Establishment and Characterization of an Acute Model of Ocular Hypertension by Laser-Induced Occlusion of Episcleral Veins. ( 28763561 )
2017
30
Caveolin-1 Protects Retinal Ganglion Cells against Acute Ocular Hypertension Injury via Modulating Microglial Phenotypes and Distribution and Activating AKT pathway. ( 28878269 )
2017
31
Acute ocular hypertension disrupts barrier integrity and pump function in rat corneal endothelial cells. ( 28761172 )
2017
32
<i>gem</i> -Dinitroalkyl Benzenes: A Novel Class of IOP-Lowering Agents for the Treatment of Ocular Hypertension. ( 29057050 )
2017
33
INTRAOCULAR DEXAMETHASONE IMPLANT POSITION IN SITU AND OCULAR HYPERTENSION. ( 29016454 )
2017
34
Uveitic Ocular Hypertension and Glaucoma. ( 29265966 )
2017
35
A 3-month safety and efficacy study of travoprost 0.004% ophthalmic solution compared with timolol in pediatric patients with glaucoma or ocular hypertension. ( 28887006 )
2017
36
Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue. ( 28053501 )
2017
37
Corneal hysteresis in patients with glaucoma-like optic discs, ocular hypertension and glaucoma. ( 28068950 )
2017
38
Thirteen-Year Follow-up of Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study. ( 27832941 )
2017
39
1,3-Oxazole-based selective picomolar inhibitors of cytosolic human carbonic anhydrase II alleviate ocular hypertension in rabbits: Potency is supported by X-ray crystallography of two leads. ( 28728897 )
2017
40
New furoxan derivatives for the treatment of ocular hypertension. ( 28027869 )
2017
41
Relationship between Elevated Intraocular Pressure and Divided Peripapillary Sector Retinal Nerve Fiber Layer Thickness in a Cynomolgus Monkey Laser-Induced Ocular Hypertension Model. ( 28564657 )
2017
42
Could White Coat Ocular Hypertension Affect to the Accuracy of the Diagnosis of Glaucoma? Relationships Between Anxiety and Intraocular Pressure in a Simulated Clinical Setting. ( 29119282 )
2017
43
JUN is important for ocular hypertension-induced retinal ganglion cell degeneration. ( 28726785 )
2017
44
Circumferential Ciliary Body Cysts Presenting as Acute Pigment Dispersion and Ocular Hypertension. ( 28914584 )
2017
45
Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients. ( 28861351 )
2017
46
Gastrodin protects retinal ganglion cells through inhibiting microglial-mediated neuroinflammation in an acute ocular hypertension model. ( 29062764 )
2017
47
Manipulating ocular endothelial tight junctions: Applications in treatment of retinal disease pathology and ocular hypertension. ( 28951125 )
2017
48
Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation. ( 28656780 )
2017
49
Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD. ( 29450400 )
2017
50
Evaluation of spectral domain optical coherence tomography parameters in ocular hypertension, preperimetric, and early glaucoma. ( 29133640 )
2017

Variations for Ocular Hypertension

Expression for Ocular Hypertension

Search GEO for disease gene expression data for Ocular Hypertension.

Pathways for Ocular Hypertension

Pathways related to Ocular Hypertension according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.41 AKT1 FOS G6PC JUN
2
Show member pathways
12.36 AKT1 FOS JUN NR3C1
3
Show member pathways
12.28 AKT1 FOS JUN PTGFR
4
Show member pathways
12 AKT1 EPO FOS JUN
5 11.99 AKT1 FOS JUN
6
Show member pathways
11.97 AKT1 FOS JUN
7 11.97 AKT1 FOS JUN
8 11.95 AKT1 FOS JUN
9
Show member pathways
11.92 AKT1 FOS JUN
10
Show member pathways
11.92 AKT1 FOS JUN
11
Show member pathways
11.91 AKT1 FOS JUN
12 11.87 AKT1 G6PC JUN
13
Show member pathways
11.87 AKT1 FOS JUN
14
Show member pathways
11.86 AKT1 FOS JUN
15 11.84 AKT1 FOS JUN
16 11.8 AKT1 FOS JUN
17
Show member pathways
11.79 AKT1 FOS JUN
18
Show member pathways
11.71 AKT1 FOS JUN
19 11.6 AKT1 FOS JUN NR3C1
20 11.59 AKT1 FOS JUN
21 11.57 AKT1 FOS JUN
22 11.56 AKT1 FOS JUN
23
Show member pathways
11.53 FOS JUN NR3C1
24
Show member pathways
11.46 AKT1 JUN NR3C1
25 11.44 AKT1 FOS JUN
26 11.44 AKT1 FOS JUN NR3C1
27 11.36 AKT1 FOS JUN
28 11.3 AKT1 G6PC NR3C1
29 11.27 AKT1 EPO FOS JUN
30 11.25 FOS JUN NR3C1
31 11.13 FOS JUN NR3C1
32 11.06 HSD11B1 HSD11B2 PTGFR
33 11.01 FOS JUN
34 10.94 AKT1 FKBP5 FOS JUN NR3C1
35 10.91 AKT1 FOS JUN
36 10.91 CA2 FOS JUN NR3C1
37 10.9 AKT1 FOS
38 10.68 FOS JUN

GO Terms for Ocular Hypertension

Cellular components related to Ocular Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor AP-1 complex GO:0035976 8.62 FOS JUN

Biological processes related to Ocular Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.62 EPO FOS JUN PTGFR
2 response to organic substance GO:0010033 9.58 AKT1 CA2 JUN
3 aging GO:0007568 9.56 AKT1 EPO FOS JUN
4 positive regulation of osteoclast differentiation GO:0045672 9.46 CA2 FOS
5 response to muscle stretch GO:0035994 9.43 FOS JUN
6 glucocorticoid biosynthetic process GO:0006704 9.37 HSD11B1 HSD11B2
7 cellular response to reactive oxygen species GO:0034614 9.33 AKT1 FOS JUN
8 cellular response to cadmium ion GO:0071276 9.13 AKT1 FOS JUN
9 response to food GO:0032094 8.8 AKT1 G6PC HSD11B2

Molecular functions related to Ocular Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcriptional activator activity, RNA polymerase II transcription factor binding GO:0001190 9.26 FOS JUN
2 11-cis retinal binding GO:0005502 9.16 OPN4 RLBP1
3 steroid binding GO:0005496 9.13 HSD11B1 HSD11B2 NR3C1
4 11-beta-hydroxysteroid dehydrogenase [NAD(P)] activity GO:0003845 8.62 HSD11B1 HSD11B2

Sources for Ocular Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....